Red Sky Partners is a team of
biotechnology industry veterans:

Geoff has over 35 years of pharmaceutical and biotechnology experience in a broad range of senior management positions in General and Operations management, as a CEO and as a member of the board of public and private companies.   Prior to joining Red Sky Partners in 2011, Geoff was Chairman, President and CEO of GTC Biotherapeutics, Inc. and prior to GTC  he was Chairman and CEO of Aronex Pharmaceuticals, Inc.  From 1984 to 1997 Geoff  held positions of increasing responsibility at Genzyme Corporation, becoming EVP responsible for Operations and the Pharmaceutical, Diagnostic and Genetics business units. Previously he was General Manager of the U.K. manufacturing operations for Gist-Brocades.

Currently Geoff is non-executive Chairman of the Board of Nabi Biopharmaceuticals, Chairman of the Board of MassBio, the Massachusetts Biotechnology Council, and is a Director of Gallus Biopharmaceuticals. He has previously served for a number of years on the Board of the Biotechnology Industry Organization and also as a member of their Emerging Companies Section and Healthcare Section Governing Body Committees. Geoff received a B.Sc.(Hons) in Biochemistry from the University of Birmingham, U.K.  and a Ph.D. in Biochemistry from the University of East Anglia, U.K.

Pamela has more than 20 years of business development and legal experience working in private and public biotechnology companies. Prior to founding Red Sky Partners in early 2009, she had her own business strategy and operations consulting practice focusin on early stage biotechnology companies. Pamela was Chief Commercial Officer at Domantis Ltd from October 2001 until its acquisition by GSK for $450M in Jan 2007. At Domantis, she was responsible for business development, IP licensing, and diligence and legal activities, including the establishment of partnerships with Abbott and Bristol-Myers Squibb and multi-party negotiations that led to the company’s sale to GSK.

Before joining Domantis, Pamela was SVP, Corporate Development at Dyax Corp, where she designed and implemented the company’s broad-based licensing program for phage display IP and technology, in addition to the negotiation and execution of multiple corporate and academic partnerships and management of IP and legal matters (including for the company’s 2000 IPO). Her prior positions include General Counsel of T Cell Sciences and Corporate Attorney for Biogen. Pamela has a BA in Biology from Cornell University and a JD from the University of Wisconsin.

Greg has 30 years experience in the medical products and biotechnology fields. In general management roles as CEO or senior executive in commercial and development stage organizations, both public and private, he has been instrumental in the successful growth and development of several prominent companies. Greg has been responsible for global commercial operations including new product launches, corporate development, and research and development. He also has extensive financing and board director experience.

Prior to founding Red Sky partners in early 2009, Greg held positions of Chairman and CEO of RenaMed Biologics, Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation, Vice President of Baxter Travenol Laboratories, and CEO of Ardais, Viagene, and ZymoGenetics. He has served on the Board of Directors of ten public and private healthcare companies and two non-profit organizations and presently serves as Chairman of the Board of Proteon Therapeutics, Inc. Greg received a B.S. in Electrical Engineering from Bradley University and an MBA from Harvard Business School.

Tim’s 25 year career in biotechnology, cell therapy and medical device general management includes experience as a founder of three start-up companies as well as senior executive assignments at two of Massachusetts’ top 20 healthcare companies. In these roles he has had extensive line management experience with a particular focus on business development transactions, new product development and launch, investor relations and corporate finance.

Prior to founding Red Sky Partners in early 2009, Tim was President and CEO of Cyberkinetics NeuroTechnology Systems, Inc. His previous positions include EVP of Haemonetics Corporation, President of Genzyme Tissue Repair, the cell therapy division of Genzyme Corporation, and EVP and CFO of BioSurface Technology. Tim serves on the Board of Directors of NeuroMetrix, Inc., a medical device company, and the Charles River School in Dover, MA. Tim received a B.A. in Biochemistry from Williams College and an M.B.A. from Harvard Business School.